ID,SUB_ID,Country,Province/State,Pop Size (N),Title,Journal,Author,Source,Language,Notes,Person Responsible,Data Request (contact person),Study start date (mm/dd/yyyy),Study end date (mm/dd/yyyy),Study length (days),Is top-level row?,Subgroup,Positive/negative cases,End-point vs Active,Survivors,Discharged,Contains Any Treatment?,ICU vs. non-ICU,Severity,Ventilation,Median Age,Mean Age,Age 95% CI Halfwidth,Age Lower Quartile,Age Higher Quartile,% Healthcare Worker,% Male,Exposure history (%),Exposure - Wuhan Travel (%),Exposure - Personal Contact (%),Incubation period (days) - Mean,Incubation period (days) - Median,Incubation period (days) - Lower Quartile,Incubation period (days) -  Higher Quartile,Time From Ill (days) - Mean,Time From Ill (days) - Median,Time from Ill (days) - Lower Quartile,Time from Ill (days) - Upper Quartile,Current smoker,Current drinker,Any Comorbidity,Hypertension,Diabetes,Coronary heart disease,Chronic obstructive lung,Cancer (Any),Carcinoma,Chronic kidney/renal disease,Other,Respiratory rate > 24 breaths per min,Pulse >=125 beats per min,Systolic blood pressure <90mm Hg,Fever (temperature ≥37·3°C),Average temperature (celsius),Max temperature (celsius),Cough,Shortness of Breath (dyspnoea),Headache,Sputum,Myalgia (Muscle Pain),Fatigue,Upper air-way congestion,Diarrhoea,Nausea or vomiting,Loss of Appetite,Sore Throat/Stuffy Nose,Chills,Disease Severity Asymptomatic,Disease Severity General,Disease Severity Severe,Disease Severity Critical,Peripheral white cell count - Median,Peripheral white cell count - Lower Quartile,Peripheral white cell count - Upper Quartile,Hemoglobin (g/L) - Median,Hemoglobin (g/L) - Lower Quartile,Hemoglobin (g/L) - Upper Quartile,"Imaging Findings Available? (yes=1, no=0)",Hematocrit,CRE (μmol/L),Lymphocyte count - Median,Lymphocyte count - Lower Quartile,Lymphocyte count - Upper Quartile,Platelet count - Median,Platelet count - Lower Quartile,Platelet count - Upper Quartile,Serum bilirubin - Median,Serum bilirubin - Lower quartile,Serum bilirubin - Upper quartile,Neutrophils,ALT (U/L),AST (U/L),GGT (U/L),CRP (mg/DL),IL-6 (ng/L),T Lymphocyte,CD4+ T Lymphocyte (Count),CD8+ T Lymphocyte (Count),Antibiotic,Antiviral,Uses lopinavir-ritonavir,Uses Favipiravir,Corticosteroid,Intravenous immunoglobin,Nasal cannula,High-flow nasal cannula oxygen therapy,Noninvasive mechanical ventilation,Invasive mechanical ventilation,ECMO,Glucocorticoid,Renal replacement therapy,Sepsis,Respiratory failure or ARDS,Respiratory failure,ARDS,Heart failure,Septic shock,Liver dysfunction,Coagulopathy,Acute cardiac injury,Acute kidney injury (AKI),Secondary infection,Hypoproteinaemia,Acidosis,Hospital admission,ICU admission,Discharged (%),"ICU length of stay, days","Hospital length of stay, days",Days to Viral Clearance (Median),Mortality,Chest CT Improve,Chest CT Same,Chest CT Decline
1,0,China,Wuhan,191,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,                    ,Agni,Cynthia,12/29/19,1/31/20,33,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,Both,56,,,46,67,,62.30%,38%,,,,,,,,11,8,14,5.76%,,47.60%,30%,19.00%,8.00%,3.00%,,1.68%,1.68%,12.00%,29.00%,1.68%,0.84%,94%,,,79%,,,23.00%,15.00%,23.03%,,4.71%,4.00%,,,,,37.70%,34.55%,27.75%,6.2,4.5,9.5,128,119,140,,,,1,0.6,1.3,206,155,262,,,,,30,,,,7.4,,,,94.76%,21.47%,,,29.84%,24.08%,,21.47%,13.61%,16.75%,1.57%,,5.24%,58.64%,,53.93%,30.89%,23.04%,19.90%,,19.37%,17.28%,14.66%,14.66%,11.52%,8.90%,,26.18%,71.73%,8,11,,28.27%,,,
1,1,China,Wuhan,54,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Non-survivors,Agni,,12/29/19,1/31/20,33,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,69,,,63,76,,70.37%,25.93%,,,,,,,,11,8,15,9.26%,,66.67%,48.15%,31.48%,24.07%,7.41%,,0.00%,3.70%,20.37%,62.96%,3.70%,0.00%,94.44%,,,72.22%,,,25.93%,14.81%,27.78%,,3.70%,5.56%,,,,,0.00%,22.22%,77.78%,9.8,6.9,13.9,126,115,138,,,,0.6,0.5,0.8,165.5,107,229,,,,,40,,,,11,,,,98.15%,22.22%,,,48.15%,66.67%,,61.11%,44.44%,57.41%,5.56%,,18.52%,100%,,98.15%,92.59%,51.85%,70.37%,,50.00%,59.26%,50.00%,50.00%,37.04%,29.63%,,72.22%,0%,8,7.5,,100.00%,,,
1,2,China,Wuhan,137,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Survivors,Agni,,12/29/19,1/31/20,33,Subgroup,Survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Both,All,Both,52,,,45,58,,59.12%,43.07%,,,,,,,,11,8,13,4.38%,,40.15%,23.36%,13.87%,1.46%,1.46%,,7.00%,0.00%,8.03%,16.06%,0.00%,0.73%,94.16%,,,81.75%,,,21.90%,15.33%,21.17%,,5.11%,2.92%,,,,,52.55%,39.42%,8.03%,5.2,4.3,7.7,128,120,140,,,,1.1,0.8,1.5,220,168,271,,,,,27,,,,6.3,,,,93.43%,21.17%,,,22.63%,7.30%,,5.84%,1.46%,0.73%,0.00%,,0.00%,42.34%,,36.50%,6.57%,11.68%,0.00%,,7.30%,0.73%,0.73%,0.73%,1.46%,0.73%,,8.03%,100%,7,12,,0.00%,,,
2,0,China,Wuhan,199,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,,Arthur,,1/18/20,2/3/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,49,68,,60.30%,,,,,,,,,13,11,16,,,,,11.60%,,,3.00%,,,,18.80%,,1%,91.50%,36.5,,,,,,,,,2.06%,4.25%,1%,,,,,,,7,5.1,9.4,,,,,,,0.9,0.6,1.2,207,158,284,,,,,33,34,,,,,,,95%,,,,,,,,14.60%,16.10%,2%,33.70%,4.50%,,,,,,,,,,,,,,,,na,10,15,,16.10%,,,
2,1,China,Wuhan,99,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,With treatment (Lopinavir - Ritonavir),Arthur,Cynthia,1/18/20,2/3/20,16,Subgroup,With treatment,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,50,68,,61.60%,,,,,,,,,13,11,17,,,,,10.10%,,,5.10%,,,,21.60%,,2%,89.90%,36.5,,,,,,,,,4.20%,9.50%,2.10%,,,,,,,7.3,5.3,9.6,,,,,,,0.8,0.6,1.4,201,155,287,,,,,33,33,,,,,,,94.90%,,94.90%,,,,,,10.10%,14.10%,2%,32.30%,3.00%,0%,12.60%,,,0%,2.10%,,,,3.20%,1.10%,,,,,na,6,14,,15.20%,,,
2,2,China,Wuhan,100,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,Control,Arthur,,1/18/20,2/3/20,16,Subgroup,Control,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,48,68,,59.00%,,,,,,,,,13,10,16,,,,,13.00%,,,1.00%,,,,16.00%,,0%,93.00%,36.5,,,,,,,,,0%,0%,0%,,,,,,,6.9,4.9,9.1,,,,,,,0.9,0.5,1.2,210,163,269.5,,,,,34,34,,,,,,,95%,,,,,,,,19.10%,18.00%,2%,35.00%,6.00%,1%,27.30%,,,1%,2.00%,,,,6.10%,6.10%,,,,,na,11,16,,17.00%,,,
3,0,China,Wuhan,81,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,"Mostly care about CT scans and their features, seems sort of unique",Arthur,,12/20/19,2/8/20,50,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,Both,50,49.5,,,,,52%,38%,,,,,,,,,,,,,26%,15%,12%,10%,11%,,,4%,,,,,73%,37.93,37.93,59%,42%,6%,19%,9%,9%,,4%,5%,1%,,,,,,,8.1,4.7,11.5,123.9,111.9,135.9,1,,,1.1,0.8,1.4,212.2,112.5,311.9,11.9,,,,46.2,40.8,,47.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77%,,12.2,,4.00%,,,
3,1,China,Wuhan,15,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 1,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,2,China,Wuhan,21,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 2,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,3,China,Wuhan,30,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 3,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,4,China,Wuhan,15,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 4,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4,0,China,Zhejiang,149,"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China",Journal of Infection,Yang et al.,https://reader.elsevier.com/reader/sd/pii/S0163445320300992?token=9163263C94899C48B765689929BEFCC2B1AD126DCC83E3753645A68BB99CF497BB124D1BB7AB61F22F586414124183AD,English,"Retrospective multi-center cohort study, Only positive cases, most not severe, over half still in hospital at end, until Feb 15th, 2020",Matthew,Cynthia,1/17/20,2/15/20,29,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,,45.11,,,,0%,54.40%,89.90%,53.69%,32.89%,,,,,6.83,,,,,,34.90%,,,,,,,,,,,,76.50%,37.86,,58.40%,1.34%,8.72%,32.20%,3.36%,,,7.38%,1.34%,,14.09%,14.09%,,,,,4.56,2.08,6.64,,,,,,66.07,1.21,0.53,1.89,174.5,96.25,252.75,9.9,3.95,15.85,2.6,20,23,5.83,7.25,,,,,22.82%,93.96%,,,,12.75%,,89.93%,1.34%,,0%,,3.36%,,,,,,,,,,,,,,100%,0%,48.99%,,,,0.00%,,,
5,0,China,Wuhan,21,Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia,Radiology,Pan et. al.,https://pubs.rsna.org/doi/full/10.1148/radiol.2020200370,English,,Ryan,,1/12/20,2/6/20,25,Top-level,Non-severe only,Positive only,End-point only,Both,Discharged only,No,ΝΑ,Mild only,Both,40,40,9,30,57,,29.00%,,,,,,,,,6,5,7,,,,,,,,,,,,,,,86%,,,57%,,,,24%,52%,,,,43%,,29%,,0%,0%,0%,4.9,4.1,5.7,,,,1,,,1.4,1,1.8,,,,,,,3.1,42,32,,17.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,17,,0.00%,,,
6,0,China,Beijing,77,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,,Ryan,,1/21/20,2/7/20,17,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,52,52,20,,,2.60%,44.16%,89.60%,70.10%,19.50%,4,4,3.5,6,5,5,3,6,,,31.20%,20.80%,7.80%,11.70%,7.79%,,,6.50%,,,,,85.70%,,,63.64%,20.80%,13.00%,,27.30%,27.30%,,1.30%,7.79%,9.10%,6.50%,,0.00%,25.97%,,,4.04,3.48,5.58,137,125,145,0,,,,,,190,149,245,,,,,28,29,,17,,,,,,,,,,,,,,,,,,,,,3.90%,2.60%,1.30%,32.47%,,,2.60%,3.90%,,,100.00%,,83.10%,,13,,6.49%,,,
6,1,China,Beijing,58,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,Non-severe,Ryan,,1/21/20,2/7/20,17,Subgroup,Non-severe only,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,45,45,17,,,3.50%,40.40%,91.20%,77.20%,14%,5,5,3.5,6,5,5,4,6,,,24.60%,14%,7.00%,5.30%,5.30%,,,3.50%,,,,,82.50%,,,57.90%,14%,17.50%,,33.30%,33.30%,,1.80%,5.30%,7%,9%,,0%,0%,0%,0.00%,3.95,3.45,4.64,139,127,144,0,,,,,,189,152,245,,,,,28,28,,13,,,,,,,,,,,,,,,,,,,,,0%,0.00%,0.00%,33.30%,,,1.80%,0.00%,,,100%,,93.10%,,12,,0.00%,,,
6,2,China,Beijing,20,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,severe,Ryan,,1/21/20,2/7/20,17,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,69,69,15,,,0%,55.00%,85%,50%,35%,3.5,3.5,3,4,6,6,5,7,,,50%,40%,10.00%,30.00%,15.00%,,,15%,,,,,95%,,,80.00%,40%,0.00%,,10.00%,10.00%,,0.00%,15.00%,15%,0%,,0%,100%,,,5.92,3.68,7.59,137,119,148,0,,,,,,198,134,272,,,,,32,36,,55,,,,,,,,,,,,,,,,,,,,,15.00%,10.00%,5.00%,30.00%,,,5.00%,15.00%,,,100%,,50%,,18.5,,25.00%,,,
7,0,China,Wuhan,36,Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study,MedrXiv,Yang et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20036780v1.full.pdf,English,"Conditioned on patients who required invasive ventilation, so high death rate",Ryan,,2/12/20,3/2/20,19,Top-level,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,69.4,69.4,21.16368,,,,83.30%,,,,,,,,,,,,,,,38.90%,27.80%,33.30%,19.40%,5.60%,,,19.44%,,,,,,,,100%,,,,,,,,,,,,100%,0%,100.00%,14,6.9,21.1,122.4,104.3,140.5,0,,,0.6,0.3,0.9,156,99.8,213,,,,12.7,34.5,30.5,,,,,,,94.40%,77.78%,,,80.60%,80.60%,,,0%,100%,,,61.10%,,,,,19.44%,,,,,22.22%,,,,100%,100%,na,,,,63.89%,,,
8,0,Italy,Nationwide,3200,"Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020",COVID-19 Surveillance Group,Palmieri et. al.,https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf,English,Conditioned on deceased patients only,Ryan,,3/1/20,3/20/20,19,Subgroup,Severe,Positive only,End-point only,Non-Survivors only,Both,No,ΝΑ,Severe/Critical Only,NA,78.5,80,,73,85,,70.60%,,,,,,,,4,,,,,,98.80%,73.80%,33.90%,30.10%,13.70%,19.50%,,20.20%,3.70%,,,,76.00%,,,40%,73.00%,,,,,,8.00%,,,,,0.00%,100.00%,0.00%,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,84%,54%,,,,,,,,,,,,,96.50%,,96.50%,,,,,10.40%,29.20%,8.50%,,,100.00%,50.00%,0%,5,4,,100.00%,,,
9,0,China,Zhejiang,91,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/20,2/16/20,27,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,,All,NA,50,,,36.5,57,0%,40.66%,98.90%,34.07%,8.79%,,6,,,,,,,,,,16.48%,8.79%,,,,,,,,,,71.43%,,,60.44%,3.30%,7.69%,32.97%,5.49%,43.96%,,23.08%,6.59%,25.27%,,,,90.10%,9.90%,,4.99,4.25,5.69,135,125,145,1,,,1.35,0.98,1.66,196,142,238,,,,2.91,18,21,,6.81,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,100.00%,9.89%,34.07%,,,,0.00%,,,
9,1,China,Zhejiang,9,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/20,2/16/20,27,Subgroup,Severe Cases,Positive only,End-point and active,Survivors only,Both,,,Severe/Critical Only,,66,,,54,80,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,0.00%,,5.23,3,5.82,130,118,142,1,,,0.9,0.7,1.3,152,127,208,,,,3.32,19.9,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,na,,,,0.00%,,,
9,2,China,Zhejiang,82,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/20,2/16/20,27,Subgroup,Mild Cases,Positive only,End-point and active,Survivors only,Both,,,Mild only,,49,,,35.3,56,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,100.00%,,4.97,4.02,5.65,135,126,147,1,,,1.4,1.05,1.75,198,144,248,,,,2.8,18,21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,na,,,,0.00%,,,
10,0,China,Seven hospitals,62,"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Limitation: most patients still in hospital when study concluded,Ryan,,1/10/20,1/26/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,41,41,,32,52,,56%,37%,37%,,4,4,3,5,2,2,1,4.3,,,32.00%,8.00%,2.00%,2%,,,,7%,13%,3%,,,77.00%,,,81.00%,3.00%,34.00%,,26%,26%,,8.00%,,,,,,,,,4.7,3.5,5.8,137,128.8,152.3,0,,,1,0.8,1.5,176,135.8,215.5,,,,2.9,22,26,,,,,,,45%,89%,6%,,26%,26%,,,,1.61%,,,,,,,2.00%,,,,,,,,,,100.00%,1.61%,2%,,,,0.00%,,,
10,1,China,Seven hospitals,33,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Subgroup >10 days,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,2,China,Seven hospitals,29,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Subgroup <=10 days,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11,1,China,Guangzhou,16,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Combination group - no exact mortality outcomes,Agni,,1/17/20,2/29/20,43,Subgroup,Combination therapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,41.8,,,,,43.80%,,,,,,,,,,,,,,12.50%,18.80%,12.50%,12.50%,0%,,0%,6.20%,12.50%,,,,,,,,,,,,,,,,,,,,,31.20%,,5.34,3.52,7.16,,,,0,,,1.83,1.01,2.65,194.8,139.7,249.9,9.23,4.26,14.2,,,,,,,,,,56.30%,100%,100%,,6.20%,68.80%,,31.20%,,0%,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
11,2,China,Guangzhou,17,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Monotherapy group - no exact mortality outcomes,Agni,,1/17/20,2/9/20,23,Subgroup,Monotherapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,47.25,,,,,58.80%,,,,,,,,,,,,,,11.76%,11.70%,17.60%,17.60%,5.90%,,0%,11.70%,5.90%,,,,,,,,,,,,,,,,,,,,,35.30%,,5.04,3.96,6.12,,,,0,,,1.36,0.84,1.88,198.6,121.4,275.8,9.51,4.65,14.37,,,,,,,,,,70.60%,100%,100%,,41.20%,76.50%,,35.30%,,0%,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
12,0,China,Jiangsu,620,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Has dynamic data (i.e. how vital signs evolved during progression of disease) at group level,Ryan,Irra,1/10/20,2/18/20,39,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,NA,,44.48,17.16,,,,52.60%,89.84%,35.00%,41.50%,6.91,6.91,,,,4.23,,,4.03%,4.84%,,15.48%,6.45%,2.10%,,1.10%,,0.60%,1.00%,,,,65.97%,37.05,,55.32%,2.58%,,26.61%,,,,8.56%,,1.90%,,,15.65%,75.81%,5.30%,3.20%,5.21,3.24,7.18,135.33,115.86,154.8,0,40.07,,1.36,0.72,2,190.47,127.4,253.54,,,,3.36,31.03,32.26,,,,,616.07,427.15,53.55%,92.90%,,,22.90%,25.20%,34.80%,2.90%,5.30%,0.80%,0.00%,22.90%,0.00%,,,8.55%,,,0.32%,,,,,,,,100.00%,3.20%,40.60%,,,,0.00%,,,
12,1,China,Jiangsu,97,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Asymptotic/mild,Ryan,Irra,1/10/20,2/18/20,39,Subgroup,Asymptomatic/Mild,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,,35.96,19.88,,,,45.40%,96.90%,24.70%,59.80%,4.49,4.49,,,,4.38,,,6.20%,5.20%,,11.30%,9.30%,3.10%,,0.00%,,0%,2.90%,,,,23.70%,36.77,,29.90%,1.00%,,12.40%,,,,4.10%,,1.00%,,,100.00%,0.00%,0.00%,0.00%,5.68,3.8,7.56,136.26,118.06,154.46,0,41.11,,1.76,1.04,2.48,218.88,142.36,295.4,,,,3.38,26.78,27.31,,,,,805.05,656.73,15.50%,85.60%,,,7.20%,9.30%,16.50%,0.00%,0.00%,0.00%,0.00%,7.20%,0.00%,,,0.00%,,,0.00%,,,,,,,,100.00%,0.00%,36.10%,,,,0.00%,,,
12,2,China,Jiangsu,470,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Moderate,Ryan,Irra,1/10/20,2/18/20,39,Subgroup,Moderate,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Both,,44.47,15.62,,,,52.60%,88.90%,36.60%,39.40%,5.1,5.1,,,,4.19,,,4.00%,4.10%,,14.30%,4.90%,1.30%,,1.30%,,0.60%,5.70%,,,,72.60%,37.09,,58.90%,2.70%,,24.70%,,,,9.20%,,2.30%,,,0.00%,100.00%,0.00%,0.00%,5.07,3.35,6.79,135.55,115.62,155.48,0,39.98,,1.35,0.78,1.92,186.82,129.11,244.53,,,,3.26,31.19,32.32,,,,,594.17,385.96,56.80%,93.60%,,,18.90%,23.00%,34.00%,0.90%,1.30%,0.00%,0.00%,18.90%,0.00%,,,0.00%,,,0.00%,,,,,,,,100.00%,2.10%,44.30%,,,,0.00%,,,
12,3,China,Jiangsu,53,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Critical,Ryan,Irra,1/10/20,2/18/20,39,Subgroup,Severe/Critical,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,,60.09,13.86,,,,66.00%,84.90%,39.60%,26.40%,4.44,4.44,,,,4.42,,,0.00%,1.90%,,34.00%,15.10%,7.50%,,1.90%,,1.90%,4.80%,,,,84.90%,37.2,,69.80%,11.30%,,41.50%,,,,11.30%,,0%,,,0.00%,0.00%,62.26%,37.74%,5.46,1.89,9.03,131.24,113.51,148.97,0,38.58,,0.7,0.38,1.02,160.95,104.91,216.99,,,,4.19,39.32,42.86,,,,,364.5,231,94.30%,100.00%,,,86.80%,73.60%,75.50%,26.40%,50.90%,9.40%,0.00%,86.80%,0.00%,,,100.00%,,,3.80%,,,,,,,,100.00%,18.90%,17.00%,,,,0.00%,,,
13,0,China,Nationwide,1099,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,"Clinical separated into severe vs. non-severe (next two rows), based on guidelines for community-acquired pneumonia, and end-point vs non-endpoint",Ted,Irra,12/11/19,1/29/20,49,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,35,58,,58.10%,,31.30%,,,4,2,7,,,1,,12.60%,,,15%,7.40%,2.50%,1.10%,0.90%,,0.70%,,,,,88.70%,,38.3,67.80%,18.70%,13.60%,33.70%,14.90%,38.10%,4.80%,3.80%,5%,,13.90%,11.50%,,84.30%,15.70%,,4.7,3.5,6,134,119,148,,,,1,0.7,1.3,168,132,207,,,,,,,,,,,,,58%,35.80%,,,18.60%,13.10%,,41.30%,5.10%,2.30%,0.50%,,0.80%,,,,3.40%,,1.10%,,,,0.50%,,,,,5.00%,5.00%,,12,,1.40%,,,
13,1,China,Nationwide,926,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/19,1/29/20,49,Subgroup,Non-Severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,Non-ventilation only,45,,,34,57,,58.20%,,31.60%,,,4,2.8,7,,,,,11.80%,,,13.40%,5.70%,1.80%,0.60%,0.80%,,0.50%,,,,,88.10%,,38.3,67.30%,15.10%,13.40%,33.40%,14.50%,37.80%,5.10%,3.50%,4.60%,,14%,10.80%,,,,,4.9,3.8,6,135,120,148,,,,1,0.8,1.4,172,139,212,,,,,,,,,,,,,53.80%,33.80%,,,13.70%,9.30%,,35.70%,0%,0%,0%,,0%,,,,1.10%,,0.10%,,,,0.10%,,,,,2.40%,5.40%,,11,,0.10%,,,
13,2,China,Nationwide,173,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/19,1/29/20,49,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,52,,,40,60,,57.80%,,30.00%,,,4,2,7,,,,,16.90%,,,23.70%,16.20%,5.80%,3.50%,1.70%,,1.70%,,,,,92%,,38.5,70.50%,37.60%,15%,35.30%,17.30%,39.90%,3.50%,5.80%,6.90%,,13.30%,15%,,,,,3.7,3,6.2,128,112,141,,,,0.8,0.6,1,137.5,99,179.5,,,,,,,,,,,,,80.30%,46.20%,,,44.50%,33.50%,,71.10%,32.40%,14.50%,2.90%,,5.20%,,,,15.60%,,6.40%,,,,2.90%,,,,,19.10%,2.90%,,13,,8.10%,,,
13,3,China,Nationwide,67,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/19,1/29/20,49,Subgroup,ICU/Venitlation/Death,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,Both,63,,,53,71,,67.20%,,35.70%,,,4,1,7.5,,,,,25.80%,,,35.80%,26.90%,9.00%,10.40%,1.50%,,3.00%,,,,,88.10%,,38.5,68.70%,53.70%,12%,29.90%,9.00%,32.80%,3.00%,6.00%,4.50%,,9%,11.90%,,,,,6.1,4.9,11.1,125,105,140,,,,0.7,0.6,0.9,156.5,114.2,195,,,,,,,,,,,,,89.60%,53.70%,,,52.20%,40.30%,,88.10%,43.30%,37.30%,7.50%,,11.90%,,,,40.30%,,13.40%,,,,40.30%,,,,,82.10%,1.50%,,14.5,,22.40%,,,
13,4,China,Nationwide,1032,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/19,1/29/20,49,Subgroup,Not (ICU/Ventilation/Death),Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Both,46,,,35,57,,57.50%,,31.10%,,,4,2,7,,,,,11.80%,,,13.70%,6.10%,2.00%,0.50%,0.90%,,0.60%,,,,,88.80%,,38.3,67.70%,16.40%,14%,33.90%,15.30%,38.50%,4.90%,3.70%,5.00%,,14.20%,11.40%,,,,,4.7,3.5,5.9,134,120,148,,,,1,0.7,1.3,169,133,207,,,,,,,,,,,,,55.90%,34.60%,,,16.40%,11.30%,,38.30%,2.60%,0.00%,0.00%,,0.10%,,,,1.00%,,0.30%,,,,1.00%,,,,,0.00%,5.20%,,12,,0.00%,,,
16,0,China,Wuhan,41,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,Fatigue and Myalgia counted as one. High flow cannula and noninvasive ventilation counted as one. Invasive and ECMO counted as one.,Kim,Irra,12/16/19,1/2/20,17,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,49,,,41,58,,73%,66%,66%,,,,,,,7,4,8,7%,,32%,15%,20%,15%,2%,2%,,,2%,29%,,,98%,,,76%,55%,,28%,44%,44%,,3%,,,,,,,,,6.2,4.1,10.5,126,118,140,1,,,0.8,0.6,1.1,164.5,131.5,263,11.7,9.5,13.9,5,32,34,,,,,,,100%,93%,,,22%,,66%,24%,24%,5%,5%,,7%,,29%,,29%,12%,,,,,7%,10%,,,100%,32%,68%,,,,15.00%,,,
16,1,China,Wuhan,13,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,,Kim,,12/16/19,1/2/20,17,Subgroup,ICU care,Positive only,End-point and active,Both,Both,Yes,ICU only,All,Both,49,,,41,61,,85%,69%,69%,,,,,,,7,4,8,0%,,38%,15%,8%,23%,8%,0%,,,0%,62%,,,100%,,,85%,92%,,38%,54%,54%,,0%,,,,,,,,,11.3,5.8,12.1,122,111,128,1,,,0.4,0.2,0.8,196,165,263,14,11.9,32.9,10.6,49,44,,,,,,,100%,92%,,,46%,,8%,62%,62%,15%,15%,,23%,,85%,,85%,31%,,,,,23%,31%,,,100%,100%,54%,,,,38.00%,,,
16,2,China,Wuhan,28,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,,Kim,,12/16/19,1/2/20,17,Subgroup,No ICU care,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,All,Both,49,,,41,57.5,,68%,64%,64%,,,,,,,7,4,8.5,11%,,29%,14%,25%,11%,0%,4%,,,4%,14%,,,96%,,,71%,37%,,23%,39%,39%,,4%,,,,,,,,,5.7,3.1,7.6,130.5,120,140,1,,,1,0.7,1.1,149,131,263,10.8,9.4,12.3,4.4,27,34,,,,,,,100%,93%,,,11%,,93%,7%,7%,0%,0%,,0%,,4%,,4%,4%,,,,,0%,0%,,,100%,0%,75%,,,,4.00%,,,
17,0,China,Wuhan,99,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",The Lancet,Chen et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext?from=Qikan_Academic_Index,English,,Kim,Irra,1/1/20,1/20/20,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,55.5,13.1,,,,68%,49%,,,,,,,,,,,,,33%,,12%,40%,1%,1%,,,17%,,,,83%,,,82%,31%,8%,,11%,,,2%,1%,,5%,,,,,,7.5,3.9,11.1,129.8,111.5,144.6,1,,,0.9,0.4,1.4,213.5,,,15.1,7.8,22.4,5,39,34,,51.4,,,,,71%,76%,,,,27%,76%,,13%,4%,3%,19%,9%,,,,,,,,,,,,,,100%,23%,31%,,,,11.00%,,,
18,1,China,Zhejiang,26,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,focus on cardiac biomarkers,Agni,Irra,2/5/20,2/13/20,8,Subgroup,Severe,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,63,,,58,69,,46.15%,,,,,,,,,,,,,,,,,0%,,,,,,100%,,,,,,,,,,,,,,,,,,,0%,100%,0%,5.93,4.77,7.45,,,,0,,64.2,,,,,,,,,,,34,32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
18,2,China,Zhejiang,8,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,focus on cardiac biomarkers,Agni,Irra,2/5/20,2/13/20,8,Subgroup,Critical,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,67,,,66,75,,62.50%,,,,,,,,,,,,,,,,,0%,,,,,,100%,,,,,,,,,,,,,,,,,,,0%,0%,100%,9.32,6.37,10.99,,,,0.00%,,82.6,,,,,,,,,,,49,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
19,0,China,Wuhan,138,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,"As of Feb 3, so much data regarding outcome can be different",Léonard,Irra,1/1/20,2/3/20,33,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,56,56,,42,68,29%,54.30%,8.70%,8.70%,,,,,,7,7,4,8,,,46.40%,31.20%,10.10%,14.50%,2.90%,7.20%,,2.90%,1.40%,,,,98.60%,,,59.40%,31.20%,6.50%,26.80%,34.80%,69.60%,,10.10%,10.10%,39.90%,,,0%,26%,0%,26.08%,4.5,3.3,6.2,,,,1,,72,0.8,0.6,1.1,163,121,191,9.8,8.4,14.1,3,24,31,,,,,,,64.40%,89.90%,,,44.90%,,76.81%,,10.90%,12.32%,2.90%,44.90%,,,19.60%,,19.60%,,8.70%,,,7.20%,3.60%,,,,100%,26%,34.10%,10,10,,4.30%,,,
19,1,China,Wuhan,36,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,ICU,Ryan,Irra,1/1/20,2/3/20,33,Subgroup,Non-ICU,Positive only,End-point and active,Survivors only,Both,Yes,ICU only,All,Both,66,66,,57,78,2.80%,61.10%,13.90%,13.90%,,,,,,8,8,4.5,10,,,72.20%,58.30%,22.20%,25%,8.30%,11.10%,,5.60%,0%,,,,100.00%,,,58.30%,63.90%,8.30%,22.20%,33.30%,80.60%,,16.70%,11.10%,66.70%,,,0%,0%,0%,0%,6.6,3.6,9.8,,,,1,,80,0.8,0.5,0.9,142,119,202,11.5,9.6,18.6,4.6,35,52,,,,,,,,94.40%,,,,,11.11%,,42%,47%,11.10%,72.20%,,,61.10%,,61.10%,,30.60%,,,22.20%,8.30%,,,,100%,100%,25.00%,10,,,17.00%,,,
19,2,China,Wuhan,102,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,Non-ICU,Ryan,Irra,1/1/20,2/3/20,33,Subgroup,ICU,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,51,51,,37,62,38.20%,52%,6.90%,6.90%,,,,,,6,6,3,7,,,37.30%,21.60%,5.90%,10.80%,1%,5.90%,,2%,2%,,,,98.00%,,,59.80%,19.60%,5.90%,28.40%,35.30%,65.70%,,7.80%,9.80%,30.40%,,,0%,100%,0%,100%,4.3,3.3,5.4,,,,1,,71,0.9,0.6,1.2,165,125,188,9.3,8.2,12.8,2.7,23,39,,,,,,,,88.20%,,,,,100%,,0%,0%,0%,35.30%,,,4.90%,,4.90%,,1.00%,,,2%,2.00%,,,,100%,0%,37%,,10,,0.00%,,,
20,0,China,Beijing,13,"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China",JAMA,Chang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761043,English,No concrete mortality data,Agni,,1/16/20,2/4/20,19,Top-level,General,Positive only,Active only,Survivors only,Both,No,ΝΑ,Mild only,NA,34,,,34,48,,77%,,,,,,,,,,,,,,,,,,,,,,,,,,92.31%,,38.4,46.30%,,23.10%,,23.10%,,61.50%,7.70%,,,,,,,0%,0%,5.83,3.51,8.15,147,134.9,159.1,0,43.2,,1.58,0.927,2.233,199,126.5,271.5,,,,3.67,,,,147,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
21,0,China,Beijing,51,Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia,Radiology,Song et al.,https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020200274,English,No data on treatments,Ryan,,1/20/20,1/27/20,7,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,Mild only,NA,,49,16,,,,49%,98%,,,,,,,,4,,,7%,,22%,10%,6%,2%,0%,0%,0%,0%,4%,,,,96%,,,47%,14%,16%,,16.50%,16.50%,,10%,6%,,,,,0%,0%,0%,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,na,,,,,,,
22,0,China,Northeast Chongqing,135,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,T-tests for difference in values between mild and severe cases,Ted,Irra,1/23/20,2/8/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,36,55,,53.40%,88.90%,,17.00%,,,,,,,,,6.70%,,31.90%,9.60%,8.90%,5.20%,0%,3%,,,,,,,88.90%,,,76.50%,13.30%,32.50%,8.80%,32.50%,32.50%,,13.30%,3%,,,,,70%,30%,,5.4,4.1,7.8,133,122,147,1,,,1.1,0.7,1.5,158,131,230,8.6,5.9,13.7,3.5,26,33.4,,10.5,,,,,43.70%,100%,,,26.70%,,,,25.20%,0.70%,0%,,3.70%,,,,15.60%,,,,,7.40%,3.70%,5.20%,,,,,11.11%,,,,0.74%,,,
22,1,China,Northeast Chongqing,95,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,,Ted,Irra,1/23/20,2/8/20,16,Subgroup,Mild,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,44,,,33,49,,54.70%,90.50%,,18.90%,,,,,,,,,8.40%,,16.30%,9.40%,3.10%,1%,0%,1%,,,,,,,90.10%,,,70.50%,9.50%,24.20%,5.30%,26.30%,26.30%,,5.30%,4.20%,,,,,,,,5.5,4,8,134,124,147,1,,,1.2,0.8,1.6,170,136,234,8.6,5.6,14,3.6,21.7,22.4,,7.7,,,,,25%,95%,,,15.80%,,,,7.40%,0%,0%,,1%,,,,1.10%,,,,,8.40%,4%,0%,,,,,10.53%,,,,0.00%,,,
22,2,China,Northeast Chongqing,40,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,,Ted,Irra,1/23/20,2/8/20,16,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,56,,,52,73,,52.50%,85.00%,,12.50%,,,,,,,,,2.50%,,70%,10%,22.50%,15%,10%,7.50%,,,,,,,85.00%,,,87.50%,18.90%,27.50%,17.50%,47.50%,47.50%,,32.50%,0%,,,,,,,,5.2,4.9,6.9,130,130,143,1,,,0.8,0.6,1,147,118,213,9.8,7.8,15.6,4.1,26.6,33.6,,91,,,,,87.50%,40%,,,52.50%,,,,67.50%,2.50%,0%,,10%,,,,50%,,,,,5%,2.50%,2.50%,,,,,12.50%,,,,2.50%,,,
23,0,China,Wuhan,17,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Overall,Ted,,1/22/20,2/10/20,19,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,All,NA,,45.1,12.8,,,,53%,65%,,,,,,,,,,,18%,18%,18%,6%,0%,0%,0%,0%,0%,0%,18%,,,,71%,,,77%,,,17.60%,24%,47%,,12%,,,,,,,,,6.2,3.7,8.7,140.5,127.4,153.6,1,,,1.1,0.6,1.6,227.1,115.5,338.7,17.7,,,4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,29%,,8.4,,0.00%,,,
23,1,China,Wuhan,5,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Discharged patients only,Ryan/Ted,,1/22/20,2/10/20,19,Subgroup,Discharged,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,NA,,34.8,9.2,,,,80%,100%,,,,,,,,,,,40%,20%,40%,0%,0%,0%,0%,0%,0%,0%,40%,,,,80%,,,60%,,,0%,60%,60%,,0%,,,,,,,,,6.3,4.8,7.8,146.3,139.6,153,1,,,1.7,1.3,2.1,295,149.3,440.7,12.2,,,3.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,8.6,,0.00%,,,
23,2,China,Wuhan,12,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Nondischarged patients,Ryan/Ted,,1/22/20,2/10/20,19,Subgroup,Non-Discharged,Positive only,Active only,Survivors only,Non-discharged only,No,ΝΑ,All,NA,,49.4,11.7,,,,41.70%,50%,,,,,,,,,,,8.30%,16.70%,8.30%,8.30%,0%,0%,0%,0%,0%,0%,8.30%,,,,66.70%,,,83.30%,,,25%,16.70%,41.70%,,16.70%,,,,,,,,,6.1,3.2,9,138.5,124.1,152.9,1,,,0.9,0.5,1.3,202,109.5,294.5,19.3,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,8.3,,0.00%,,,
24,0,China,Wuhan,48,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,All patients had high-sensitivity cardiac troponin I.,Kim,,12/25/19,2/15/20,52,Top-level,General,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,NA,,70.58,13.38,,,,68.70%,,,,,,,,,,,,,,,66.70%,20.80%,27.10%,,,,10.40%,14.60%,,,,70.80%,,,,,,,,,,,,,,,,54.20%,45.80%,,6.485,4.145,8.825,122.92,101.9,143.94,0,,,0.985,0.62,1.308,167,116,217.5,,,,4.6,21,32,,43.2,,,,,95.80%,97.90%,,,45.80%,12.50%,60.40%,,37.50%,2.10%,,,,,,,,,,,,,,,,,100%,,0.6458,,,,35.42%,,,
24,1,China,Wuhan,17,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,,Kim,,12/25/19,2/15/20,52,Subgroup,Non-survivor,Positive and Negative/Unconfirmed,End-point and active,Non-Survivors only,Both,Yes,Both,All,NA,,78.61,8.31,,,,70.60%,,,,,,,,,,,,,,,70.60%,29.40%,23.50%,,,,29.40%,17.60%,,,,70.60%,,,,,,,,,,,,,,,,23.50%,76.50%,,8.84,5.46,9.67,111.35,87.39,135.31,0,,,0.92,0.51,1.29,119,88.5,212.5,,,,3.9,19,33,,65.5,,,,,100.00%,100.00%,,,47.10%,23.50%,11.80%,,82.40%,5.90%,,,,,,,,,,,,,,,,,100%,,na,,,,100.00%,,,
24,2,China,Wuhan,31,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,,Kim,,12/25/19,2/15/20,52,Subgroup,Survivor,Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Both,All,NA,,66.16,13.66,,,,67.70%,,,,,,,,,,,,,,,64.50%,16.10%,29.00%,,,,0.00%,12.90%,,,,71.00%,,,,,,,,,,,,,,,,71.00%,29.00%,,5.74,4.14,7.39,29.26,112.86,145.66,0,,,1.08,0.66,1.33,181,146,220,,,,4.9,23,32,,23.8,,,,,93.50%,96.80%,,,45.20%,6.50%,87.10%,,12.90%,0.00%,,,,,,,,,,,,,,,,,100%,,na,,,,0.00%,,,
25,0,USA,Washington,21,Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State,JAMA,Arentz et al.,https://jamanetwork.com/journals/jama/fullarticle/2763485,English,,Kim,,2/20/20,3/5/20,14,Top-level,,Positive only,End-point and active,Both,Both,Yes,ICU only,All,NA,,70,,,,,52%,,,,,,,,,,,,,,86%,,33.30%,,33.30%,,,47.60%,42.90%,,,,52%,37.6,39.2,48%,76%,,,,,,,,,,,,,,,5.15,1.74,12.22,114,80,137,1,,,0.889,0.2,2.39,215,52,395,,,,,26.5,34,,,,,,,,,,,,,,4.80%,19%,71%,,,,,,,,,,14.30%,,,19.10%,19.10%,,,,100%,9.50%,,,,67.00%,,,
26,0,Singapore,Singapore,18,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/20,2/25/20,33,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,47,,,31,73,0%,50%,100%,100%,,,,,,,,,,,,28%,28%,11%,,,,,,,,,,72%,37.7,39.6,83%,11%,,,,,,17.00%,22.20%,,61%,,,,,,4.6,1.7,6.3,13.5,11.7,17.2,0,,,1.2,0.8,1.7,159,116,217,,,,2.7,,,,16.3,,,,,,27.78%,,,,,,,6%,,,,,,,,,,,,,,,,,,,11.10%,44.44%,0.33,,,0.00%,,,
26,1,Singapore,Singapore,12,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/20,2/25/20,33,Subgroup,Did not require supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,37,,,31,56,0%,58%,100%,100%,,,,,,,,,,,,8%,8%,8.30%,,,,,,,,,,58%,38.3,39.6,83%,8%,,,,,,25.00%,,,67.00%,,,,,,4.6,1.7,6.3,13.9,11.7,17.2,0,,,1.2,0.8,1.6,159,128,213,,,,2.8,,,,11.1,,,,,,,,,,,,,6%,,,,,,,,,,,,,,,,,,,0.00%,41.67%,0,,,0.00%,,,
26,2,Singapore,Singapore,6,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/20,2/25/20,33,Subgroup,Required supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,56,,,47,73,0%,33%,100%,100%,,,,,,,,,,,,67%,67%,16.70%,,,,,,,,,,100%,37.3,38.1,83%,17%,,,,,,0.00%,,,50%,,,,,,3.4,2.6,5.8,13.2,11.7,14,0,,,1.1,0.8,1.7,156,116,217,,,,1.8,,,,65.6,,,,,,,,,,,,,6%,,,,,,,,,,,,,,,,,,,33.30%,50.00%,1,,,0.00%,,,
27,0,Italy,Nationwide,355,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy,JAMA,Onder et al.,https://jamanetwork.com/journals/jama/fullarticle/2763667?appId=scweb,English,Only case fatality rates by age (reporting on subsample with chart review),Ryan,,2/15/20,3/17/20,31,Top-level,Non-survivor,Positive only,End-point and active,Non-Survivors only,Discharged only,No,ΝΑ,All,Both,80,79.5,,,,,70%,,,,,,,,,,,,,,98.20%,,35.50%,30%,24.50%,20.30%,,,10%,,,,,,,,,,,,,,,,,,,0%,100%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,50%,0%,,,,100.00%,,,
28,0,China,Wuhan,201,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,All patients,Ryan,Irra,12/25/19,1/26/20,32,Top-level,aggregate,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,51,,,43,60,,63.70%,49.30%,49.30%,,,,,,,,,,,,,19.40%,10.90%,4%,2.50%,0.50%,,1%,7%,,,,93.50%,38.8,,81.10%,,,,32.30%,32.30%,,,,,,,,,,,5.94,3.37,7.18,,,,0,,,0.91,0.6,1.29,180,137,241.5,,,,4.47,31,33,,48.1,6.98,,353,236,97.50%,84.60%,,,,,48.72%,,30.34%,2.51%,0.50%,,0.00%,,,,41.80%,,,,,,,,,,100.00%,26.40%,71.64%,,13,,21.89%,,,
28,1,China,Wuhan,84,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Patients with ARDS,Ryan,Irra,12/25/19,1/26/20,32,Subgroup,with ARDS,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Ventilation only,58.5,,,50,69,,71.40%,,,,,,,,,,,,,,,27.40%,19%,6%,,,,,,,,,92.90%,39,,81%,,,,32.10%,32.10%,,,,,,,,,,,5.02,3.37,7.18,,,,0,,,1.08,0.72,1.45,178,140,239.5,,,,3.06,27,30,,23.4,6.29,,371,234,98.80%,76.20%,,,,,20.20%,,72.60%,6%,1.20%,,0%,,,,100%,,,,,,,,,,100.00%,63.10%,16.67%,,,,52.38%,,,
28,2,China,Wuhan,117,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Patients without ARDS,Ryan,Irra,12/25/19,1/26/20,32,Subgroup,without ARDS,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Non-ventilation only,48,,,40,54,,58.10%,,,,,,,,,,,,,,,13.70%,5.10%,2.60%,,,,,,,,,94.00%,38.6,,82.20%,,,,32.50%,32.50%,,,,,,,,,,,8.32,5.07,11.2,,,,0,,,0.67,0.49,0.99,187,124.5,252.5,,,,7.04,35,38,,83,7.39,,241,157.5,96.60%,90.60%,,,,,69.20%,,0%,0%,0%,,0%,,,,0%,,,,,,,,,,100%,0%,100%,,,,0.00%,,,
30,1,China,Xi'an,17,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bien et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,"Does not report mortality, but has data over time",Agni,,2/3/20,2/10/20,7,Subgroup,meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,51,,,49,67,,64.70%,,58.80%,5.90%,,,,,,,,,5.90%,,52.90%,35.30%,17.60%,5.90%,5.90%,,,,,41.20%,,,94.10%,,37.7,52.90%,58.80%,,5.90%,58.80%,58.80%,,11.80%,,,,,,23.50%,35.30%,41.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,94.10%,,,,,,,,,,,,,,,,,,,,,,,,76.47%,,,,,,,
30,2,China,Xi'an,11,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bien et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,"Does not report mortality, but has data over time",Agni,,2/3/20,2/10/20,7,Subgroup,no meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,64,,,43,67,,45.50%,,36.40%,18.20%,,,,,,,,,9.10%,,36.40%,27.30%,0%,18.20%,0,,,,,45.50%,,,100%,,37.7,63.60%,63.60%,,18.20%,45.50%,45.50%,,9.10%,,,,,,36.40%,36.40%,27.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.90%,100%,,,63.60%,,,,,,,,,,,,,,,,,,,,,,,,36.36%,,,,,,,
31,0,China and outside China,,507,Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population- level observational study,Lancet,Sun et al.,https://www.thelancet.com/action/showPdf?pii=S2589-7500%2820%2930026-1,English,data available here: https://docs.google.com/spreadsheets/d/1Gb5cyg0fjUtsqh3hl_L-C5A23zIOXmWH5veBklfSHzg/edit#gid=447265963,Yuchen,Irra,1/20/20,1/31/20,11,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,46,,35,60,,55%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,7.89%,,,
32,0,China,Beijing,262,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,,Agni,Irra,1/20/20,2/10/20,21,Top-level,All cases,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,47.5,,,,,,48.50%,92%,40.50%,49.20%,,6.7,,,,,,,,,,,,,,,,,,,,,82.10%,,37.7,45.80%,6.90%,6.50%,,,26.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,81.70%,,17.20%,,,,0.90%,,,
32,1,China,Beijing,46,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,,Agni,,1/20/20,2/10/20,21,Subgroup,severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,61.4,,,,,,56.50%,89.10%,28.30%,56.50%,,7.5,,,,,,,,,,,,,,,,,,,,,80.40%,,37.7,54.30%,32.60%,6.50%,,,32.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.10%,,4.30%,,,,6.50%,,,
34,0,China,Wuhan,5,Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation,Journal of Infection,Ye et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301146,English,Not relevant now (only repeat cases). Individual patient level,EXCLUDE,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32,2,China,Beijing,216,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,"contains 192 mild cases, 11 non-pneumonia cases, 13 asymptomatic cases",Agni,,1/20/20,2/10/20,21,Subgroup,common,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,Mild only,NA,44.5,,,,,,46.80%,92.60%,43.10%,47.70%,,6.5,,,,,,,,,,,,,,,,,,,,,82.40%,,37.7,44.00%,1.40%,6.50%,,,25.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,80.10%,,19.90%,,,,0.00%,,,
33,0,China,Wuhan,9,Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records,Lancet,Chen et al.,https://www.sciencedirect.com/science/article/pii/S0140673620303603,English,"Not applicable for now specific to pregnant women (probably too specific for now) - isolated data per patient, could be useful if we decide to create a dataset with personalized information",EXCLUDE,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
35,1,China,Anhui,6,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/20,2/3/20,13,Subgroup,Mild,Positive only,End-point and active,,Both,Yes,,Mild only,,,29.2,10.9,,,,50%,,67%,33%,,,,,,,,,,,,,,,,,,,,,,,83%,,,67%,,0%,17%,,67%,,,,0,11%,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
35,2,China,Anhui,43,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/20,2/3/20,13,Subgroup,Common,Positive only,End-point and active,,Both,Yes,,Mild only,,,33.4,12.2,,,,65%,,67%,28%,,,,,,,,,,,,,,,,,,,,,,,93%,,,84%,,11%,51%,,72%,,,,19%,7%,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
35,3,China,Anhui,21,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/20,2/3/20,13,Subgroup,Severe,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,44.2,12,,,,48%,,85%,10%,,,,,,,,,,,,,,,,,,,,,,,95%,,,86%,,10%,67%,,81%,,,,43%,10%,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
35,4,China,Anhui,3,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/20,2/3/20,13,Subgroup,Critical,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,63,21.2,,,,0%,,100%,,,,,,,,,,,,,,,,,,,,,,,,100%,,,67%,,33%,67%,,100%,,,,100%,0%,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
36,1,China,Shenzhen,35,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,Engineering,Cai et al.,https://www.sciencedirect.com/science/article/pii/S2095809920300631,English,treatment study; only improve/decline,Holly,,1/24/20,2/14/20,21,Subgroup,FPV,Positive only,End-point only,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,43,,,35.5,59,,40.00%,57.10%,57.10%,,,,,,,,,,,,,,,,,,,,,,,,62.90%,,,34.30%,,8.60%,,,,,2.90%,,,17.10%,0%,,,,,8.1,3.8,6.6,,,,1,,,1.5,1,1.8,,,,,,,3,21.6,24.1,26.9,15,14,1.0467,593.3,397.8,,100%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,na,,,4,0.00%,91.43%,6.45%,3.23%
36,2,China,Shenzhen,45,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,Engineering,Cai et al.,https://www.sciencedirect.com/science/article/pii/S2095809920300631,English,treatment study; only improve/decline,Holly,,1/24/20,2/14/20,21,Subgroup,LPV/RTV,Positive only,End-point only,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,49,,,36,61,,46.70%,57.80%,57.80%,,,,,,,,,,,,,,,,,,,,,,,,82.20%,,,22.20%,,11.10%,,,,,0%,,,4.40%,2.20%,,,,,4.3,3.4,4.9,,,,1,,,1.2,0.9,1.4,,,,,,,2.6,22.6,25.8,24.4,21.4,12.9,0.9252,542.3,326.4,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,11,0.00%,62.22%,17.78%,20.00%
37,1,China,Beijing,9,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/20,2/21/20,51,Subgroup,Mild,Positive only,End-point and active,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,78%,,89%,11%,,,,,,,,,,,,,,,,,,,,,,,67%,,,33%,,,11%,0%,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
37,2,China,Beijing,28,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/20,2/21/20,51,Subgroup,Moderate,Positive only,End-point and active,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,54%,,57%,39%,,,,,,,,,,,,,,,,,,,,,,,96%,,,39%,,,14%,14%,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
37,3,China,Beijing,10,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/20,2/21/20,51,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,,,,,,,70%,,60%,40%,,,,,,,,,,,,,,,,,,,,,,,80%,,,40%,,,10%,30%,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
37,4,China,Beijing,3,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/20,2/21/20,51,Subgroup,Critically Severe,Positive only,End-point and active,Both,Both,No,ICU only,Severe/Critical Only,Both,,,,,,,0%,,0%,67%,,,,,,,,,,,,,,,,,,,,,,,67%,,,67%,,,33%,33%,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,
38,0,China,Shanghai,249,"Clinical progression of patients with COVID-19 in Shanghai, China",Journal of Infection,Chen et al. ,https://www.sciencedirect.com/science/article/pii/S0163445320301195,English,no subgroups; doesn't discuss treatments,Ryan,Irra,1/20/20,2/6/20,17,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,NA,51,51,,36,64,,50.60%,,,,,,,,4,4,2,7,,,36.10%,21.70%,,,,0.40%,,,16.40%,,,,87.10%,,,36.50%,7.60%,11.20%,,,15.70%,,3.20%,,3.20%,6.40%,,2.80%,10%,5%,5%,4.71,3.8,5.86,,,,1,,12,1.12,0.79,1.49,,,,,,,,23,25,,12,,,431,256.54,,,,,,,,,,,,,,,,,3.20%,,,,,,,,,,,8.80%,86.30%,,16,,0.80%,,,
39,1,China,Zhejiang,72,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,non-intesive and intensive ventilation reported together.,Kim,Irra,1/17/20,2/8/20,22,Subgroup,Normal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,34.9,14.2,,,,45.80%,,91.70%,8.30%,,,,,,,,,,,16.70%,5.60%,5.60%,0%,0%,0%,,0%,4.20%,,,,66.70%,,,45.80%,0,2.80%,23.60%,7%,12.50%,,11.10%,,,23.60%,,,,,,5.42,3.42,7.42,141.04,125.42,156.66,1,,,1.39,0.78,2,198.44,140,256.88,9.11,4.25,13.97,3.48,25.53,26.67,,2.3,,,,,,77.80%,,,,,11.10%,,0,0,0%,0%,0%,,,,0%,,,8.30%,,,0%,,,,,0%,na,,,,,,,
39,2,China,Zhejiang,573,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,include imaging findings,Kim,,1/17/20,2/8/20,22,Subgroup,Abnormal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,46.65,13.82,,,,51.50%,,81.00%,19%,,,,,,,,,,,28.80%,16.80%,7.70%,1%,0%,1%,,1%,6.50%,,,,85.90%,,,68.40%,4.50%,11.30%,36%,11.50%,19%,,7.90%,,,14%,,,,,,5.01,3.14,6.88,138.09,121.62,154.56,1,,,1.23,0.71,1.75,185.22,122.8,247.64,11.26,3.22,19.3,3.29,29.37,30.08,,8.8,,,,,,85.20%,,,,,43.60%,,1.60%,1.60%,0%,13.40%,0%,,,,2.40%,,,13.10%,,,0.30%,,,,,0.70%,na,,,,,,,
40,1,China,Changzhou,15,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,Intl Journal of Innfectious Diseases,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,English,"breakdown by contact (direct vs. secondary, tertiary transmission)",Kim,,1/23/20,2/18/20,26,Subgroup,Imported contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,35,,,29,51,,66.70%,,,,,8,4,10,,,,,,,0%,,0%,0%,0%,,,0%,0%,,,,73.30%,,,33.30%,13.30%,,20%,26.70%,6.70%,,13.30%,,,,,,100%,,,5.2,4.6,6.3,,,,0,,,1.5,0.9,2.1,,,,,,,,22.9,19,,4.4,,,399,287,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
40,2,China,Changzhou,17,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,,,Kim,,1/23/20,2/18/20,26,Subgroup,Secondary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,37,,,24,47.5,,41.20%,,,,,8,4,11,,,,,,,23.50%,,5.90%,11.80%,0%,,,5.90%,0%,,,,58.80%,,,52.90%,5.90%,,35.30%,11.80%,0%,,5.90%,,,,,,100%,,,4.8,3.4,6.2,,,,0,,,1.1,1,1.9,,,,,,,,13.5,17,,2.2,,,375,267,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
40,3,China,Changzhou,19,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,,,Kim,,1/23/20,2/18/20,26,Subgroup,Terciary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,53,,,35,65,,42.10%,,,,,12,9,14,,,,,,,42.10%,,15.80%,15.80%,5.30%,,,0%,5.30%,,,,68.40%,,,47.40%,5.30%,,21.10%,10.50%,10.50%,,10.50%,,,,,,100%,,,3.9,3.1,5.7,,,,0,,,1.3,0.9,1.6,,,,,,,,25.2,22,,7,,,374,303,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
41,0,China,Xiaogan,114,Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area,COVID-19) in the Xiaogan area,Wang et al.,https://www.sciencedirect.com/science/article/pii/S000992602030088X,English,include CT findings but not outcomes/treatment received,Agni,Irra,1/25/20,2/9/20,15,Top-level,All,Positive only,Active only,Both,Both,No,ΝΑ,Mild only,NA,53,,,23,78,,50.90%,78.90%,,,,,,,,,,,,,52.60%,28.90%,13.20%,6.10%,4.40%,0.90%,,,5.30%,,,,93.90%,,38.6,79.80%,23.70%,,7.90%,,,,2.70%,,,5.30%,,,100.00%,0.00%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
42,0,China,Shandong,537,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,Yuchen,Irra,1/19/20,2/15/20,27,Top-level,,Positive only,End-point and active,,,,,,,,,,,,,55.70%,,,,,,,,,,,,,,,,,,,,,,,,,,87.90%,,,35.90%,,,,,8.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.40%,,,
42,1,China,Shandong,,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,,,,,Subgroup,Common,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,2,China,Shandong,,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,,,,,Subgroup,Severe,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43,0,China,Hubei,49,湖北省十堰市新型冠状病毒肺炎 49 例临床分析,第三军医大学学报,赵琴，雷旭，刘龙，占国清，李儒贵，李金科，李芳，杜卫星，李健，杨靖， 谭华炳,DOI：10.16016/j.1000-5404.202002107,Chinese,,Yuchen,Irra,1/23/20,2/9/20,17,Top-level,,Positive only,,,,,,,,48,,,,,,51.02%,,91.80%,,,,,,,,,,,,36.73%,,,,,,,,,,,,87.76%,,,65.31%,12.24%,24.49%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,0,China,,463,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,Yuchen,Irra,1/1/20,2/6/20,36,Top-level,survival,Positive only,Active only,Survivors only,,Yes,ICU only,All,,51,,,,,,52.70%,,,,,12,9,14,,,,,,,44.28%,23.10%,8.64%,6.05%,,,,,,,,,89.63%,38.5,40.5,77.06%,41.90%,13.17%,31.53%,,28.08%,,,,,,,,,,,5.44,4.09,7.52,126,114,126,,,,1.07,0.76,1.46,212,155,285,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12,,0.00%,,,
44,1,China,,,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,,,,,,Subgroup,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,2,China,,,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,,,,,,Subgroup,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
45,0,China,,76,76例新型冠状病毒肺炎患者的临床及CT影像特征分析,中医杂志,陈甜，蒋宗焰，许炜，张清,,Chinese,,Yuchen,Irra,,,0,Subgroup,,Positive only,End-point and active,,,Yes,ICU only,All,,62,,,,,,55.30%,,,,,,,,,,,,,,,,,,,,,,,,,,75%,,,67.11%,18.42%,,,,38.16%,,,,,6.58%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.94%,,,
46,0,China,Henan,524,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,Yuchen,Irra,2/1/20,2/20/20,19,Top-level,,Positive only,,,,Yes,,All,,45,,,33,55,,58.00%,,54.80%,62.20%,,10,6,15,,,,,,,,,,,,,,,,,,,47.30%,,,12.79%,26.34%,5.53%,11.07%,5.15%,31.30%,,2.67%,4.20%,,16.79%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,1,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/2/20,2/21/20,19,Subgroup,Common,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,2,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/3/20,2/22/20,19,Subgroup,Severe,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,3,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/4/20,2/23/20,19,Subgroup,Critical,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,0,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/20,2/23/20,30,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,46.5,,30.4,62.6,,47.10%,,28.70%,34.10%,,,,,5,,,,15.70%,,24.20%,11.20%,8.10%,0.40%,0.40%,,,,4%,3.10%,,,53.40%,,,50.70%,6.70%,4.90%,12.10%,5.40%,5.40%,,5.40%,,,,,,,,,,,,135.1,,,,,69.4,1.5,,,199.8,,,18.8,,,,20,30,,,,1.5,,,,100%,,,,,58.30%,,5.40%,1.30%,,7.60%,,,,,,,,,,,,,,,,,50.20%,,14,11.9,0.00%,,,
47,1,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/20,2/23/20,30,Subgroup,Common,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,Both,,44.9,,28.9,60.9,,45.30%,,27.60%,37.50%,,,,,4,,,,15.60%,,20.80%,10.90%,5.20%,0.50%,0.50%,,,,3.60%,1.00%,,,47.90%,,,49.50%,0,5.20%,10.40%,5.20%,5.20%,,6.30%,,,,,,,,,,,,135.9,,,,,69.5,1.5,,,197.8,,,19.2,,,,20,26,,,,1.5,,,,100%,,,,,63.50%,,0,0,,9%,,,,,,,,,,,,,,,,,52.60%,,13.8,11.7,0.00%,,,
47,2,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/20,2/23/20,30,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,Both,,56.4,,44,68.8,,58.10%,,35.50%,12.90%,,,,,6,,,,16.10%,,45.20%,12.90%,25.80%,0,0,,,,6.50%,16.10%,,,87.10%,,,58.10%,48.40%,3.20%,22.60%,6.50%,6.50%,,0,,,,,,,,,,,,130.1,,,,,68.2,1,,,211.8,,,17.5,,,,34,60,,,,1,,,,100%,,,,,25.80%,,38.70%,9.70%,,54.80%,,,,,,,,,,,,,,,,,35.50%,,16.4,13.9,0.00%,,,
48,0,China,Jiangxi,49,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/20,1/27/20,6,Top-level,All,Positive only,,,,,,All,,,42.9,,,,,67.32%,93.89%,,,4.7,,,,6.7,,,,6.12%,,28.60%,12.20%,4.10%,,,,,,12.20%,,,,78.70%,37.1,39.1,38.80%,,12.20%,,,18.40%,,4.10%,,,14.90%,16.30%,,81.63%,,,5.52,,,,,,,,,,,,,,,,,,3.84,22.7,27.4,,27.77,,,312.16,174.74,,15.38%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,1,China,Jiangxi,40,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/20,1/27/20,6,Subgroup,Common,Positive only,,,,,,Mild only,,,40.6,,,,,62.50%,97.50%,,,4.7,,,,,,,,7.50%,,,5.00%,0,,,,,,15%,,,,80.00%,37.2,,32.50%,,10.00%,7.50%,,15.00%,,5.00%,,,17.50%,12.50%,,,,,4.61,,,,,,,,,,,,,,,,,,2.96,20.7,25.1,,16.05,,,352.75,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,2,China,Jiangxi,9,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/20,1/27/20,6,Subgroup,Severe/Critical,Positive only,,,,,,Severe/Critical Only,,,53,,,,,88.90%,77.78%,,,4.5,,,,,,,,0,,,44.44%,22.22%,,,,,,,,,,66.67%,36.9,,66.67%,,22.22%,44.44%,,33.33%,,0,,,0,33.33%,,,,,9.56,,,,,,,,,,,,,,,,,,7.76,32,38.1,,79.86,,,221.32,145.35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,41,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,,1/24/20,43854,,reference data from another paper,Positive only,,,,,Both,All,,49,,,,,,73.00%,,,,,,,,,,,,,,32.00%,,,,,,,,,,,,98.00%,,,76.00%,,,,44%,44%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,99,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,,1/30/20,43860,,reference data from another paper,Positive only,,,,,,,,,55.5,,,,,,,,,,,,,,,,,,,51.00%,,,,,,,,,,,,83.00%,,,82.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,138,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,,,0,,reference data from another paper,Positive only,,,,,Both,,,56,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,98.60%,,,59.40%,,,,,69.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26.10%,,,,,,,,
49,0,China,,26,26例新型冠状病毒肺炎确诊病例临床和流行病学特征,中华医院感染学杂志,"庄英杰,陈竹,李进,杨兴龙,李靖,袁月,管群,贾红军,马婧怡,吴丹,马洪滨,汤紫荣",,Chinese,,Zhen,Irra,2020/01/??,before 02/12/2020,#VALUE!,Top-level,,Positive only,,,,,,,,,39.77,,,,,76.50%,,53.85%,46.15%,,,,,,,,,,,42.30%,15.38%,11.54%,,,,,,15.38%,,,,76.92%,,,30.77%,,23.08%,11.54%,26.92%,53.85%,,11.54%,,,15.38%,11.54%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,0,China,,308,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/20,2/20/20,26,Top-level,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,,,52.95324675,,38.73733766,,,47.81%,,,,,,,,,,,,,,,,,,,,,,,,,,82.00%,,,95.00%,,,,,67.90%,,10.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.21626328,,5.19%,,,
50,1,China,,34,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,65.1,,51.8,78.4,,54.54%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.40909091,,36.36%,,,
50,2,China,,87,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,58.4,,43.1,73.7,,54.02%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.43103448,,4.60%,,,
50,3,China,,98,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,45.8,,31.9,59.7,,43.88%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,99.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.4,,0.00%,,,
50,4,China,,90,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,50.3,,36.6,64,,43%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.7,,0.00%,,,
51,0,China,Hunan,697,湖南省 697 例新型冠状病毒肺炎确诊病例就诊及诊断分析,实用预防医学,刘子言，高立冬，胡世雄，罗垲炜，肖洁华，赵善露，曾舸，戴志辉，杨浩， 孙倩莱，张恒娇，邓志红,,Chinese,"No Treatment or Outcome, Can discard",Michael,Irra,12/21/19,2/13/20,54,Top-level,,Positive only,Active only,Both,Both,No,Both,All,Both,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,0,China,Meta-study (might be possible to extract more data by looking at references in paper),"44,672",新型冠状病毒肺炎流行病学特征分析,中华流行病学杂志,中国疾病预防控制中心新冠状病毒肺炎应急响应机制流行病学组,http://html.rhhz.net/zhlxbx/004.htm,Chinese,EXCLUDE,EXCLUDE,Irra,12/31/19,2/11/20,42,Top-level,,Positive only,Active only,Both,Both,No,Both,All,Both,,50.92,,35,75,3.80%,51.40%,,85.20%,,,,,,,,,,,,26%,12.80%,5.30%,4.20%,2.40%,0.50%,,,,,,,,,,,,,,,,,,,,,,,80.90%,13.80%,4.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.30%,,,
53,0,China,Guangdong,188,Evidence and characteristics of human-to-human transmission of 2019-nCoV,MedRxiv,Kang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/02/06/2020.02.03.20019141.full.pdf,English,Patient level data in supplementary materials,Sam,,1/1/20,1/27/20,26,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,48.8,,,,,49.50%,,75%,,5.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84.50%,12.20%,3.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
54,0,China,Various,9,Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China,JAMA,Wei et. al.,https://doi.org/10.1001/jama.2020.2131,English,"Only <1yr old, minimal data",Holly,,12/8/19,2/6/20,60,Top-level,All,Positive only,End-point and active,Survivors only,,No,Non-ICU only,Mild only,Non-ventilation only,0.58,0.56,,0.33,0.75,,22%,87.50%,,,,,,,,,,,,,,,,,,,,,,,,,44%,,,22%,,,11%,,,,,,,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
55,0,China,Wuhan,1,A new coronavirus associated with human respiratory disease in China,Nature,Fan et. al,https://www.nature.com/articles/s41586-020-2008-3?fbclid=IwAR10YjXQeW795Vke_56S0Qz-eZzCXSosAAYpF6vuWjWH8vnGIUKWJr1BkoI,English,One patient (see Table 1); only use if we get desperate,Holly,,12/26/19,1/7/20,12,Top-level,All,Positive only,Active only,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,41,41,,,,,100%,100%,100%,,,,,,6,,,,,,,,,,,,,,,,,,100%,,38.4,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,4.1,,,,,100%,100%,,,,,,,,100%,,,,,,,,,,,,,,,,,,100%,na,3,,,,,,
56,0,China,Wuhan,10,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,Can split by survivors/non survivors,Agni,,1/1/20,2/11/20,41,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.3,3.5,5.1,138,121,151,0,,,0.7,0.6,0.9,165,135,219,,,,2.8,24,26,,12.1,17,,,,100%,60%,60%,,50%,,,100%,,,,,,,,,,,,,,,,,,,,,60%,,,,20.00%,,,
56,1,China,Wuhan,8,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,,Agni,,1/1/20,2/11/20,41,Subgroup,Survivors,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.2,3.2,5,138,126,150,0,,,0.8,0.7,0.9,167,150,221,,,,2.6,21,23,,10.1,13,,,,100%,,75%,,37.50%,,,100%,,,,,,,,,,,,,,,,,,,,,75%,,,,0.00%,,,
56,2,China,Wuhan,2,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,,Agni,,1/1/20,2/11/20,41,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.6,3.5,5.7,137,128,146,0,,,0.7,0.6,0.8,170,121,219,,,,4.3,28,30,,25.5,21,,,,100%,,0%,,100%,,,100%,,,,,,,,,,,,,,,,,,,,,0%,,,,100.00%,,,
57,0,China,Guizhou,162,"Epidemiologic Characteristics of COVID-19 in Guizhou, China",MedRxiv,Ping et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20028944v1.full.pdf,English,"No treatment or outcomes, and features very sparse. Recommend dropping",Ted,,1/21/20,2/16/20,26,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,37,,,,,,50.62%,91.35%,51.85%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
58,0,China,Shanghai,148,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,Split by liver functions,Ted,,1/20/20,1/31/20,11,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,50.5,,,36,64,,49.30%,,,,,,,,,5,3,7,,,,,,,,,,,,,,,70.30%,,,45.30%,,,26.70%,,,,4.10%,2%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16%,39.20%,21%,,,,,,,,,,,,,,,,,44.60%,,,,,,,,,62.84%,,12,,0.68%,,,
58,1,China,Shanghai,75,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,,Ted,,1/20/20,1/31/20,11,Subgroup,Abnormal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,62.67%,,,,,,,,,,,,,,,,,,,,,,,,,,76%,,,46.67%,,,22.67%,,,,,,,,,,,,,4.99,,,,,,,,,0.925,0.635,1.734,,,,,,,,,,,,,,336,201,22.67%,45.33%,31.00%,,,,,,,,,,,,,,,,,,,,,,,,,,59%,,15.14,,,,,
58,2,China,Shanghai,73,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,,Ted,,1/20/20,1/31/20,11,Subgroup,Normal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,38.36%,,,,,,,,,,,,,,,,,,,,,,,,,,64%,,,43.84%,,,27.34%,,,,,,,,,,,,,4.3,,,,,,,,,1.32,1.734,1.57,,,,,,,,,,,,,,492,273,9.59%,32.88%,11%,,,,,,,,,,,,,,,,,,,,,,,,,,81%,,12.67,,,,,
59,0,China,Wuhan,82,Clinical characteristics of 82 death cases with COVID-19,MedRxiv,Zhang et. al.,https://www.medrxiv.org/content/10.1101/2020.02.26.20028191v1.full.pdf,English,,Agni,,1/11/20,2/10/20,30,Top-level,Only non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,72.5,,,65,80,,65.90%,,,,,7,4,10,,,,,,,76.80%,56.10%,18.30%,20.70%,14.60%,7.30%,,7.30%,12.20%,,,,78%,38.8,,64.60%,63.40%,,,,46.30%,,12.20%,2.30%,,4.90%,,,,,100%,,,,,,,,,,0.5,0.3,0.8,148.5,102,206,13.6,10,22.9,6.8,,,,,,,,,100%,100%,,,35.30%,,,100%,36.60%,4.80%,,,,28%,,100%,,24.60%,,,,,,,,,100%,17.10%,0%,,5,,100.00%,,,100%
60,0,China,Jiangxi,11,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Can split by naive/experienced,Matthew,,2/12/20,3/19/20,36,Top-level,All Survive,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,,,,,,,36.40%,18.20%,,9.10%,,,,,,,,,,,18.20%,18.20%,,,,,,,,,,,36.40%,,,36.40%,63.60%,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,17.81,,0.00%,,,
60,1,China,Jiangxi,2,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Naive had no prior drugs,Matthew,,2/12/20,3/19/20,36,Subgroup,Naive,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,31,,,18,44,,50.00%,50.00%,,,,,,,,,,,,,0.00%,0.00%,,,,,,,,,,,0.00%,,,50.00%,50.00%,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,8,,0.00%,,,
60,2,China,Jiangxi,9,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Prior antiviral therapy,Matthew,,2/12/20,3/19/20,36,Subgroup,Experienced,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,44,,,18,66,,33.30%,11.10%,,11.10%,,,,,,,,,,,22.20%,22.20%,,,,,,,,,,,44.40%,,,33.30%,66.60%,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,20,,0.00%,,,
61,1,China,Two provinces,163,A comparative multi­center study on the clinical and imaging features of confirmed and unconfirmed patients with COVID­19,MedRxiv,Miao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040782v1.full.pdf,English,This study provides results for unconfirmed and confirmed; I would just report on confirmed,Léonard,,1/12/20,2/13/20,32,Subgroup,Confirmed,Positive only,Active only,Survivors only,Non-discharged only,Yes,Both,All,Both,43.8,,,,,,51.60%,,71%,38.60%,7,,,,,,,,24.80%,16.80%,,13.90%,5%,2%,3%,1%,,0%,,,,,79%,,,59.70%,4.80%,8.10%,16.10%,24.20%,24.20%,4.80%,11.30%,,,8.10%,,4.80%,,,6.50%,5.3,4,6.7,138.8,122.1,155.5,1,,,1.3,0.9,1.8,178,130.5,215.5,9.7,7.4,13.1,2.9,22,25.5,,9.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0.00%,,,
62,0,China,Chongqing,167,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,Can split by both severity and age (tables 2-3 report results for severe and asymptomatic by age),Arthur,,1/1/20,3/1/20,60,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,,,32.20%,49.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74.80%,13.10%,0%,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,16.68,,0.00%,,,
62,1,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 0-14,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,100.00%,9,,,,,,,,0.00%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,4.66,3.81,5.5,,,,0,,,2.925,1.91,3.94,140.5,30,251,,,,,,,,,,,811,561,,,,,,,,,,,,,,,,,0,0,,0.00%,,,0,,,,,,100%,,16.5,,0.00%,,,
62,2,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 15-29,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,50.00%,50.00%,8.5,,,,,,,,0.00%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,3.9,,,,,,0,,,1.63,1.21,2.05,166,,,,,,46.80%,,,,,,,691,537,,,,,,,,,,,,,,,,,0,0,,0.00%,,,0,,,,,,100%,,10.5,,0.00%,,,
62,3,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,50.00%,0.00%,20.5,,,,,,,,50.00%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,7.105,5.11,9.1,,,,0,,,2.135,1.31,2.96,229,221,237,,,,62.15%,,,,,,,420,,,,,,,,,,,,,,,,,,0,0,,0.00%,,,0,,,,,,100%,,16,,0.00%,,,
62,4,China,Chongqing,6,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,66.70%,8.8,,,,,,,,33.30%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,5.9,4.11,6.27,,,,0,,,1.3,0.96,1.99,183,87,328,,,,63.00%,,,,,,,433,370,,,,,,,,,,,,,,,,,0,16.70%,,0.00%,,,0,,,,,,100%,,12.2,,0.00%,,,
62,5,China,Chongqing,5,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,80.00%,7,,,,,,,,40.00%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,6.42,6.68,9.4,,,,0,,,2.04,2.03,3,197,192,198,,,,62.50%,,,,,,,253,,,,,,,,,,,,,,,,,,0,0,,0.00%,,,0,,,,,,100%,,11.6,,0.00%,,,
62,6,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Asymptomatic 70+,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,100.00%,13.7,,,,,,,,0.00%,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,100.00%,0.00%,0%,0%,5.19,5.17,8.05,,,,0,,,0.83,0.78,2.57,,,,,,,69.20%,,,,,,,273,,,,,,,,,,,,,,,,,,0,0,,0.00%,,,0,,,,,,100%,,19,,0.00%,,,
62,7,China,Chongqing,7,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Severe 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,71.40%,28.60%,9.1,,,,,,,,28.60%,,,,,,,,,,,,,,100%,,,71.40%,14.30%,57.10%,,,57.10%,,,,,,,0.00%,0.00%,100%,0%,5.29,4.1,8.2,,,,0,,,2.19,0.67,2.97,205.5,133,503,,,,60.30%,,,,,,,399,342,,,,,,,,,,,,,,,,,0,0,,14.30%,,,0,,,,,,100%,,18.3,,0.00%,,,
62,8,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Severe 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,66.70%,33.30%,8.3,,,,,,,,0.00%,,,,,,,,,,,,,,66.70%,,,66.70%,33.30%,0,,,0%,,,,,,,0.00%,0.00%,100%,0%,3.3,3.26,3.34,,,,0,,,0.855,0.75,0.96,186,174,233,,,,60.70%,,,,,,,393,304,,,,,,,,,,,,,,,,,0,0,,0,,,0,,,,,,100%,,17,,0.00%,,,
62,9,China,Chongqing,5,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Severe 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,80.00%,20.00%,12.3,,,,,,,,20%,,,,,,,,,,,,,,80%,,,60%,60%,20%,,,20%,,,,,,,0.00%,0.00%,100%,0%,5.17,3.2,6.07,,,,0,,,0.78,0.75,1.07,77,68,86,,,,72.30%,,,,,,,167,235,,,,,,,,,,,,,,,,,0,0,,20%,,,0,,,,,,100%,,26.5,,0.00%,,,
62,10,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Severe 60-69,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,0.00%,33.30%,,,,,,,,,66.70%,,,,,,,,,,,,,,33.30%,,,66.70%,66.70%,100%,,,100%,,,,,,,0.00%,0.00%,100%,0%,6.34,5.43,6.68,,,,0,,,0.69,0.63,1.43,158,131,356,,,,82.70%,,,,,,,117,121,,,,,,,,,,,,,,,,,0,0,,0,,,0,,,,,,100%,,15.7,,0.00%,,,
62,11,China,Chongqing,4,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/20,3/1/20,60,Subgroup,Severe 70-79,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,50.00%,50.00%,10.3,,,,,,,,25%,,,,,,,,,,,,,,50%,,,75%,100%,50%,,,50%,,,,,,,0.00%,0.00%,100%,0%,3.05,2.25,3.85,,,,0,,,0.5,0.4,0.97,130.5,121,140,,,,69.80%,,,,,,,121,111,,,,,,,,,,,,,,,,,0,0,,25%,,,0,,,,,,100%,,21.25,,0.00%,,,
63,0,China,Wuhan,403,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,,Kim,,1/30/20,2/25/20,26,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,NA,,56,,39,68,,47.90%,,,,,,,,,,,,7.20%,10.20%,43.40%,28%,14.10%,8.90%,6.90%,,,1.70%,9.70%,,,,79.20%,,,10.20%,2%,,,0.50%,3.50%,,1.00%,0.50%,,2%,,,,,,5.5,4.11,7.3,126.9,109.2,144.6,1,,,1.06,0.75,1.49,192,148,251,12.8,10,17.5,3.57,,,,25.5,,,,,86.60%,97.80%,,,,49.10%,,26.30%,13.90%,5.70%,,41.20%,,,35.50%,,,,,21.60%,,20.60%,14.10%,19.20%,,,100%,,75.19%,,,,24.81%,,,
63,1,China,Wuhan,100,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf ,English,,Kim,,1/30/20,2/25/20,26,Subgroup,Died,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,All,NA,,71,,65,80,,57%,,,,,,,,,,,,9%,10%,77%,60%,25%,16%,17%,,,3%,22%,,,,87%,,,4%,2%,,,0%,2%,,1.00%,0%,,0%,,,,,,8.58,5.13,12.34,125,105.4,144.6,1,,,0.73,0.46,0.92,169,121,219,17.4,12.7,24.7,7.09,,,,95,,,,,99%,96%,,,,66%,,74%,48%,16%,,74%,,,90%,,,,,71%,,65%,43%,58%,,,100%,,0%,,,,100.00%,,,
63,2,China,Wuhan,303,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,,Kim,,1/30/20,2/25/20,26,Subgroup,Discharged,Positive only,End-point only,Both,Discharged only,Yes,Both,All,NA,,49,,37,62,,44.90%,,,,,,,,,,,,6.60%,10.20%,32.30%,17.50%,10.60%,6.60%,3.60%,,,1.30%,5.60%,,,,76.60%,,,12.20%,2%,,,0.70%,4%,,1.00%,0.70%,,2.60%,,,,,,5.03,3.98,6.5,127.5,110.4,144.6,1,,,1.18,0.9,1.62,205,153,264,11.9,9.5,15.4,3.1,,,,23.8,,,,,82.90%,98.30%,,,,43.60%,,10.60%,2.60%,2.30%,,30.40%,,,17.50%,,,,,5.30%,,5.90%,4.60%,6.30%,,,100%,,100%,,,,0.00%,,,
64,0,China,Qingdao/Wuhan,74,Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019,MedRxiv,Wu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20027078v1.full.pdf,English,Pediatric cases only,Kim,,1/20/20,2/27/20,38,Top-level,,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,NA,,6,,0.1,15.08,,59.46%,,,95.59%,,,,,,,,,0%,0%,0%,,,,,,,,,,,,27.03%,38.6,40.1,32.43%,2.70%,2.70%,2.70%,0%,6.76%,,4.05%,,4.05%,,,40.54%,,,,7.68,,,,,,1,,,3.73,,,,,,,,,,,,,1.9,,,,,35.52%,,0%,0%,1.30%,,,0%,1.30%,0%,0%,0%,0%,,,,,,,,,,,,,,100%,,100%,,11,,0.00%,,,
65,0,Japan (Diamond Princess),International,104,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/20,2/26/20,15,Top-level,General,Positive only,,Survivors only,Both,,,All,,68,,,46.75,75,,,,,,,,,,,,,,,,50%,,6.70%,,,,3.80%,,,,,,28.80%,,,27.90%,6.70%,9.60%,,,,,7.70%,,,15.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
65,1,Japan (Diamond Princess),International,76,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/20,2/26/20,15,Subgroup,"Non-severe (asymptomatic, mild)",Positive only,,Survivors only,Both,,,Mild only,,66.5,,,44.75,74,,,,,,,,,,,,,,14.50%,,44.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,
65,2,Japan (Diamond Princess),International,28,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/20,2/26/20,15,Subgroup,Severe,Positive only,,Survivors only,Both,,,Severe/Critical Only,,72.5,,,55.25,76.5,,,,,,,,,,,,,,25%,,64.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,6.10%,,,,,,,,1.22%,,,1.22%,2.44%,,,,,,,,,,na,,,,,,,
66,0,South Korea,Nationwide,7755,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,"More data on fatalities, so might make more sense to only report on this subset; might also be more data on the KCDC website",Matthew,,2/11/20,2/26/20,15,Top-level,,Positive only,,Both,Both,No,,All,NA,,,,,,,38%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,1.00%,,,
66,1,South Korea,Nationwide,66,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,"More data on fatalities, so might make more sense to only report on this subset; might also be more data on the KCDC website",Matthew,,2/11/20,2/26/20,15,Subgroup,Died,Positive only,,Non-Survivors only,Non-discharged only,No,,All,NA,77,,,45,84,,56%,,,,,,,,,4.5,0,11,,,97%,,,15.90%,,11.10%,,7.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,100.00%,,,
67,0,China,Wuhan,82,"The clinical and epidemiological features and hints of 82 confirmed COVID-19 pediatric cases aged 0-16 in Wuhan, China",MedRxiv,Yu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.15.20036319v1.full.pdf,English,,Galit,,2/1/20,2/20/20,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,4,3.39,,0,6,0,62.20%,,100%,,,,,,,,,,0%,0%,9%,,,,,,,,9%,,,,62.19%,,,62.19%,2.44%,,,,,,,,,,,9.76%,,,,8.76,,,,,,0,,,,,,248,,,,,,,34.57,44.43,64.97,18.22,30.66,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,9.80%,73.17%,,11.2,,0.00%,,,
68,0,China,Wuhan,158,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/20,2/25/20,55,Top-level,All,Positive only,End-point only,Both,Both,Yes,Both,All,Both,66,,,56,73.3,,55.70%,13.90%,0.60%,13.30%,,,,,,8,4,13,5.70%,3.20%,,43%,50%,18.40%,8.20%,4.40%,,10.10%,5.10%,,,,81%,,,60.80%,41.10%,3.20%,,13.90%,58.20%,,11.40%,3.80%,53.20%,,,,,,,5.9,4.2,8.1,,,,1,,,0.94,0.62,1.23,197,138,267,11.4,8.3,15.9,3.9,26,28.5,,37.9,,,356,171,85.40%,98.70%,,,,22.80%,,64.60%,15.80%,7.60%,0,39.90%,,,,,29.70%,,27.80%,,,34.80%,12%,32.30%,,,100.00%,22.80%,na,,13,,27.80%,,,
68,1,China,Wuhan,79,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/20,2/25/20,55,Subgroup,non-diabetic,Positive only,End-point only,Both,Both,Yes,Both,All,Both,66,,,56,74,,55.70%,20.30%,0%,20.30%,,,,,,8,5,12,6.30%,3.80%,,25.30%,0%,10.10%,8.90%,3.80%,,10.10%,2.50%,,,,79.70%,,,57%,40.50%,5.10%,,7.60%,50.60%,,13.90%,1.30%,50.60%,,,,,,,6,4,8,,,,1,,,1,0.63,1.29,209,158,273,11.7,8.4,15.9,3.8,27.5,30,,35,,,374,222,83.50%,98.70%,,,,21.50%,,62%,8.90%,5.10%,0,39.20%,,,,,20.30%,,20.30%,,,22.80%,6.30%,21.50%,,,100%,15.20%,na,,13,,20.30%,,,
68,2,China,Wuhan,79,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/20,2/25/20,55,Subgroup,diabetic ,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,66,,,56,73,,55.70%,7.60%,1.30%,6.30%,,,,,,8,4,14,5.10%,2.50%,,60.80%,100%,26.60%,7.60%,5.10%,,10.10%,7.60%,,,,82.30%,,,64.60%,41.80%,1.30%,,20.30%,65.80%,,8.90%,6.30%,55.70%,,,,,,,5.8,4.5,8.2,8.2,6.6,9,1,,,0.81,0.56,1.22,185,133.5,259.3,11,7.9,16,4.3,25.5,27.5,,39.9,,,280,142,87.30%,98.70%,,,,24.10%,,67.10%,22.80%,10.10%,0,40.50%,,,,,39.20%,,35.40%,,,46.80%,17.70%,43%,,,100%,30.40%,na,,13,,35.40%,,,
68,3,China,Wuhan,51,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/20,2/25/20,55,Subgroup,diabetic - survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Both,All,Both,63,,,55,70,,49%,5.90%,2.00%,3.90%,,,,,,8.5,4,15,2%,2%,,49%,100%,17.60%,3.90%,3.90%,,11.80%,2%,,,,84.30%,,,66.70%,33.30%,2%,,23.50%,62.70%,,11.80%,5.90%,54.90%,,,,,,,5.3,4,7.1,7.6,6.6,8.6,1,,,0.97,0.71,1.38,197,146,289,9.5,7.8,13.4,3.4,27,24,,15.3,,,382,157,80.40%,87.30%,,,,19.60%,,58.80%,7.80%,2%,0,33.30%,,,,,5.90%,,2%,,,19.60%,0%,25.50%,,,100%,11.80%,na,,16,,0.00%,,,
68,4,China,Wuhan,28,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/20,2/25/20,55,Subgroup,diabetic - non survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,74.5,,,64.3,81.8,,67.90%,10.70%,0%,10.70%,,,,,,8,3,13,10.70%,3.60%,,82.10%,100%,42.90%,14.30%,7.10%,,7.10%,17.90%,,,,78.60%,,,60.70%,57.10%,0%,,14.30%,71.40%,,3.60%,7.10%,57.10%,,,,,,,8,5.5,13.6,9.9,7.8,11,1,,,0.7,0.38,0.82,174,114,202,14.2,8,24.3,6.9,23,41,,86.1,,,202.5,78,100%,100%,,,,32.10%,,82.10%,50%,25%,0,53.60%,,,,,100%,,96.40%,,,96.40%,50%,75%,,,100%,64.30%,na,,5,,100.00%,,,
69,0,China,Shenzhen,6,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Top-level,All,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,All,Non-ventilation only,50,46.17,17.98436475,36,65,0%,50%,33%,0%,33%,4.5,4.5,3,6,7.8,7,7,9,,,66.67%,33.33%,16.67%,0%,0%,16.67%,0%,0%,16.67%,,,,83.33%,37.7,,83.33%,,,,50%,50%,16.67%,33.33%,,,16.67%,,,16.67%,16.67%,0%,5.2,4.3,6.5,148,131,152,1,,,1.7,0.7,2.7,196.5,166.75,201,,,,4.05,19.23,24.18,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,83.33%,0%,0%,0%,,,0.00%,,,
69,1,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,65,65,,65,65,0%,0%,100%,0%,100%,,,,,7,7,7,7,,,100%,100%,0%,0%,0%,100%,0%,0%,0%,,,,100%,39,,100.00%,,,,100%,100%,0%,0%,,,0%,,,0%,0%,0%,4.8,4.8,4.8,131,131,131,1,,,0.6,0.6,0.6,157,157,157,,,,4,14.2,20.5,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,
69,2,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,66,66,,66,66,0%,100%,0%,0%,0%,,,,,6,6,6,6,,,100%,100%,0%,0%,0%,0%,0%,0%,0%,,,,100%,39,,100.00%,,,,100%,100%,0%,0%,,,0%,,,100%,100%,0%,4.2,4.2,4.2,156,156,156,1,,,0.7,0.7,0.7,118,118,118,,,,3.2,13.9,23.3,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,
69,3,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,37,37,,37,37,0%,0%,100%,0%,100%,,,,,9,9,9,9,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,100%,36.2,,100.00%,,,,0%,0%,100%,100%,,,100%,,,0%,0%,0%,5.6,5.6,5.6,150,150,150,1,,,2.2,2.2,2.2,224,224,224,,,,3.1,25.9,27.4,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,
69,4,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,36,36,,36,36,0%,100%,0%,0%,0%,,,,,10,10,10,10,,,100%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,36.5,,100%,,,,0%,0%,0%,100%,,,0%,,,0%,0%,0%,11.4,11.4,11.4,152,152,152,1,,,2.7,2.7,2.7,196,196,196,,,,8.1,20.2,18.1,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,
69,5,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Asymptomatic; not admitted to hospital,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,10,10,,10,10,0%,100%,0%,0%,0%,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,0%,36.5,,0%,,,,0%,0%,0%,0%,,,0%,,,0%,0%,0%,6.5,6.5,6.5,146,146,146,1,,,2.8,2.8,2.8,197,197,197,,,,3.2,23.9,28.2,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,0%,0%,0%,0%,,,0.00%,,,
69,6,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/20,1/24/20,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,63,63,,63,63,0%,0%,0%,0%,0%,,,,,7,7,7,7,,,100%,0%,100%,0%,,0%,0%,0%,0%,,,,100%,39,,100%,,,,100%,100%,0%,0%,,,0%,,,0%,0%,0%,4.3,4.3,4.3,130,130,130,1,,,1.2,1.2,1.2,205,205,205,,,,2.7,17.3,27.6,,,,,,,100%,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,
70,1,China,Wuhan,101,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,Todo: add subgroups depending on course of disease,Galit,,1/1/20,2/15/20,45,Subgroup,All,Positive only,End-point only,Non-Survivors only,,Yes,,Severe/Critical Only,Both,71,,,60,80,,59.41%,100%,100%,,,,,,,,,,,,82%,58.42%,21.78%,24%,13.86%,7%,,11%,0%,,,,81.19%,,,55.45%,99.01%,4.95%,,6%,35.64%,,10%,3%,,,,0%,0%,0%,100%,9.7,9.042,10.358,,,,1,,,0.76,0.681,0.839,178.2,167.37,189.03,25.01,18.324,31.696,8.466,55.99,116.8,,107.9,,0.76,195.6,130.4,98%,96%,,,,,,,40.59%,13.86%,,,4.95%,,,,,,,,,,,,,,100%,,0%,,,,100.00%,,,
71,1,China,Wuhan,55,"Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series",Lancet,Yao et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550019,English,,Galit,,1/26/20,2/18/20,23,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,,Yes,,Severe/Critical Only,Both,65,70.7,,60,80,0%,67%,100%,100%,,,,,,,,,,,,73%,60%,26%,,22%,7%,,9%,0%,,,,96%,,,62%,96%,4%,,93%,93%,,4%,4%,,,,0%,0%,0%,100%,7.85,4.84,12.79,125,105,145,1,,,0.55,0.41,0.8,160.5,93.3,227.7,14.1,8.6,19.9,7.58,25,43,44,84.9,,0.55,,,96%,,,,,,,,21.80%,,,,7.30%,,,,,,,,,,,,,,100%,,0%,,,,100.00%,,,
72,0,China,Wuhan,140,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/20,2/3/20,18,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,57,,,30,75,2.10%,50.70%,10.70%,0%,0%,,,,,8,8,7,10,1.40%,,64.30%,30%,12.10%,5.00%,1.40%,,,,10%,,,,91.70%,,,75%,36.70%,,,,75%,36.70%,12.90%,17.30%,12.20%,,,,41.40%,,,4.7,3.7,6.7,,,,1,,34.2,0.8,0.7,1,,,,,,,,,,,34.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
72,1,China,Wuhan,82,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/20,2/3/20,18,Subgroup,Nonsevere,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,51.5,,,31,71,3.70%,46.30%,13.40%,0%,0%,,,,,8,8,6,10,0%,,53.70%,24.40%,11.00%,3.70%,0%,,,,10%,,,,88.10%,,,76.10%,29.90%,,,,76.10%,29.90%,11.00%,23.20%,11.00%,,,,0%,,,4.5,3.5,5.9,,,,1,,28.7,0.8,0.7,1.1,,,,,,,,,,,28.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
72,2,China,Wuhan,58,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/20,2/3/20,18,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,64,,,33,77,0%,56.90%,6.90%,0%,0%,,,,,7,7,6,10,3.40%,,79.30%,37.90%,13.80%,6.90%,3.40%,,,,10%,,,,96.20%,,,73.60%,45.30%,,,,73.60%,45.30%,15.80%,8.80%,14.00%,,,,100%,,,5.3,4,9,,,,1,,47.6,0.7,0.6,0.9,,,,,,,,,,,47.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,
73,0,China,Wuhan,36,"Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China",MedRxiv,Huang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/03/05/2020.02.27.20029009.full.pdf,English,,Sam,,1/21/20,2/14/20,24,Top-level,All,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ΝΑ,Severe/Critical Only,NA,69.22,69.22,18.890544,62.8844,75.5556,,69.44%,,,,,,,,,,,,11.11%,,,58.33%,19.44%,13.89%,11.11%,2.78%,,8.33%,,,,,94.44%,,,77.78%,58.33%,,22.22%,2.78%,47.22%,,8.33%,,,,,,0%,100%,0%,7.67,4.1,10.97,123.74,111.14294,136.33706,0,,,0.67,0.44758,0.89242,167.21,115.39962,219.02038,11.21,7.5,19.2,6.64,26,43,,106.2,100.6,,,,100%,97.22%,,,,55.56%,,97.22%,52.78%,25%,,69.44%,,,100%,,100%,,,,,,2.78%,,,,100%,,0%,,,,100.00%,,,
74,0,Chile,Chile,922,SITUACIÓN EPIDEMIOLÓGICA COVID-19. CHILE al 23 de marzo de 2020,Departamento de Epidemiología. Ministerio de Salud de Chile,Departamento de Epidemiología. Ministerio de Salud de Chile,https://www.dropbox.com/s/cj3p12oncrewh72/Informe_10_COVID_19_Chile.pdf.pdf.pdf?dl=0,Spanish,,Galit,Galit,3/1/20,3/23/20,22,Top-level,All,Positive only,End-point and active,Both,,,,,,34,,,29,47,,49%,,,,,,,,,,,,,,,,,,,,,,,,,,9%,,,52%,57%,52%,,4%,,,,47%,,45%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.20%,,na,,,,0.20%,,,
75,0,USA,Nationwide,12,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,,Ryan,,1/20/20,2/22/20,33,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,Both,53,,,,,,67%,100%,75%,17%,,,,,1,1,0,3,8.33%,,16.67%,16.67%,8.33%,16.67%,8.33%,0.00%,0%,0%,33.33%,,,,58.33%,,,66.67%,8.33%,25%,,,41.67%,,8.33%,,,8.33%,8.33%,0%,58.33%,50%,8.33%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0%,0%,,,,,,,,58.33%,8.33%,92%,4,12.71428571,29,0%,,,
75,1,USA,Nationwide,7,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,,Ryan,,1/20/20,2/22/20,33,Subgroup,Hospitalized patients,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,55,,,,,,71.40%,100%,,,,,,,2,1,1,3,14.28%,,57.14%,14.28%,14.28%,14.28%,14.28%,0%,0%,0%,28.57%,,,,85.27%,,38.544,85.71%,14.28%,14.28%,,,28.57%,,14.28%,,,,,0%,100%,85.72%,14.28%,3.65,3.3,3.9,,,,1,,,,,,,,,,,,,180,120.14,,,,,,,71.42%,42.85%,0%,0%,0%,0%,,14.28%,,,,,,0%,,,,0%,0%,,,,,,,,100%,14.28%,86%,4,12.71,32,0%,,,
76,0,China,,36,Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming,MedRxiv,,10.1101/2020.02.28.20029173,English,"binned labs, no deaths",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,,China,,109,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,,10.1101/2020.02.17.20024166,English,broken down by ARDS,Holly,,,,,Top-level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,56,,,,,,,,,,,,Subgroup,non-ARDS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,53,,,,,,,,,,,,Subgroup,ARDS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,,China,,24,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",MedRxiv,,10.1101/2020.02.20.20025619,English, asymptomatic,Holly,,,,,Top-level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,5,,,,,,,,,,,,Subgroup,Symptomatic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,19,,,,,,,,,,,,Subgroup,Asymptomatic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79,,China,,25,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,,10.1101/2020.02.19.20025239,English,"all deaths, patient-level data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
80,,China,,51,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,,10.1101/2020.02.20.20025536,English,incl detailed lab data,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,,China,,110,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,,10.1101/2020.03.02.20029306,English,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
82,,China,,46,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,,10.1101/2020.03.10.20032136,English,adolescents/young adults,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
83,,China,,64,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",MedRxiv,,10.1101/2020.03.09.20033118,English,all medical staff,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,,China,,48,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,,10.1101/2020.02.26.20028084,English,"home monitoring, could be good for milder cases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,,China,,104,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,,10.1101/2020.03.04.20026005,English,include detailed outcomes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,,Scotland,,1,The index case of SARS-CoV-2 in Scotland: a case report,Journal of Infection,Hill et. al.,https://doi.org/10.1016/j.jinf.2020.03.022,English,"Only one patient, but very detailed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87,,UK,England,2,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Both patients reported seperately,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,,USA,Illinois,1,First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.,The Lancet,Ghinai et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30607-3/fulltext,English,Lab test results reported in body of paper (not in tables),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,,South Korea,,28,Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea,Osong Public Health and Research Perspectives,Osong Public Health Dept,https://ophrp.org/journal/view.php?doi=10.24171/j.phrp.2020.11.1.03,English,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,